541 related articles for article (PubMed ID: 29191561)
1. Epitope-Specific Immunotherapy Targeting CD4-Positive T Cells in Celiac Disease: Safety, Pharmacokinetics, and Effects on Intestinal Histology and Plasma Cytokines with Escalating Dose Regimens of Nexvax2 in a Randomized, Double-Blind, Placebo-Controlled Phase 1 Study.
Daveson AJM; Ee HC; Andrews JM; King T; Goldstein KE; Dzuris JL; MacDougall JA; Williams LJ; Treohan A; Cooreman MP; Anderson RP
EBioMedicine; 2017 Dec; 26():78-90. PubMed ID: 29191561
[TBL] [Abstract][Full Text] [Related]
2. Epitope-specific immunotherapy targeting CD4-positive T cells in coeliac disease: two randomised, double-blind, placebo-controlled phase 1 studies.
Goel G; King T; Daveson AJ; Andrews JM; Krishnarajah J; Krause R; Brown GJE; Fogel R; Barish CF; Epstein R; Kinney TP; Miner PB; Tye-Din JA; Girardin A; Taavela J; Popp A; Sidney J; Mäki M; Goldstein KE; Griffin PH; Wang S; Dzuris JL; Williams LJ; Sette A; Xavier RJ; Sollid LM; Jabri B; Anderson RP
Lancet Gastroenterol Hepatol; 2017 Jul; 2(7):479-493. PubMed ID: 28506538
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of gluten peptide-based antigen-specific immunotherapy (Nexvax2) in adults with coeliac disease after bolus exposure to gluten (RESET CeD): an interim analysis of a terminated randomised, double-blind, placebo-controlled phase 2 study.
Tye-Din JA; Daveson AJM; Goel G; Goldstein KE; Hand HL; Neff KM; Popp A; Taavela J; Maki M; Isola J; Williams LJ; Truitt KE; Anderson RP;
Lancet Gastroenterol Hepatol; 2023 May; 8(5):446-457. PubMed ID: 36898393
[TBL] [Abstract][Full Text] [Related]
4. Randomised clinical trial: a placebo-controlled study of subcutaneous or intradermal NEXVAX2, an investigational immunomodulatory peptide therapy for coeliac disease.
Truitt KE; Daveson AJM; Ee HC; Goel G; MacDougall J; Neff K; Anderson RP
Aliment Pharmacol Ther; 2019 Sep; 50(5):547-555. PubMed ID: 31407810
[TBL] [Abstract][Full Text] [Related]
5. A Sensitive Whole Blood Assay Detects Antigen-Stimulated Cytokine Release From CD4+ T Cells and Facilitates Immunomonitoring in a Phase 2 Clinical Trial of Nexvax2 in Coeliac Disease.
Hardy MY; Goel G; Russell AK; Chen Yi Mei SLG; Brown GJE; Wang S; Szymczak E; Zhang R; Goldstein KE; Neff KM; Williams LJ; Truitt KE; Dzuris JL; Tye-Din JA; Anderson RP
Front Immunol; 2021; 12():661622. PubMed ID: 34093551
[TBL] [Abstract][Full Text] [Related]
6. Safety and tolerability of KAN-101, a liver-targeted immune tolerance therapy, in patients with coeliac disease (ACeD): a phase 1 trial.
Murray JA; Wassaf D; Dunn K; Arora S; Winkle P; Stacey H; Cooper S; Goldstein KE; Manchanda R; Kontos S; Grebe KM
Lancet Gastroenterol Hepatol; 2023 Aug; 8(8):735-747. PubMed ID: 37329900
[TBL] [Abstract][Full Text] [Related]
7. T-cell response to gluten in patients with HLA-DQ2.2 reveals requirement of peptide-MHC stability in celiac disease.
Bodd M; Kim CY; Lundin KE; Sollid LM
Gastroenterology; 2012 Mar; 142(3):552-61. PubMed ID: 22108197
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of AMG 714 in adults with coeliac disease exposed to gluten challenge: a phase 2a, randomised, double-blind, placebo-controlled study.
Lähdeaho ML; Scheinin M; Vuotikka P; Taavela J; Popp A; Laukkarinen J; Koffert J; Koivurova OP; Pesu M; Kivelä L; Lovró Z; Keisala J; Isola J; Parnes JR; Leon F; Mäki M
Lancet Gastroenterol Hepatol; 2019 Dec; 4(12):948-959. PubMed ID: 31494096
[TBL] [Abstract][Full Text] [Related]
9. Resistance to celiac disease in humanized HLA-DR3-DQ2-transgenic mice expressing specific anti-gliadin CD4+ T cells.
de Kauwe AL; Chen Z; Anderson RP; Keech CL; Price JD; Wijburg O; Jackson DC; Ladhams J; Allison J; McCluskey J
J Immunol; 2009 Jun; 182(12):7440-50. PubMed ID: 19494267
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis and evaluation of high-affinity binders for the celiac disease associated HLA-DQ2 molecule.
Kapoerchan VV; Wiesner M; Hillaert U; Drijfhout JW; Overhand M; Alard P; van der Marel GA; Overkleeft HS; Koning F
Mol Immunol; 2010 Feb; 47(5):1091-7. PubMed ID: 19962195
[TBL] [Abstract][Full Text] [Related]
11. A randomized, double-blind, placebo-controlled, multicenter, repeat-dose study of two intravenous acetaminophen dosing regimens for the treatment of pain after abdominal laparoscopic surgery.
Wininger SJ; Miller H; Minkowitz HS; Royal MA; Ang RY; Breitmeyer JB; Singla NK
Clin Ther; 2010 Dec; 32(14):2348-69. PubMed ID: 21353105
[TBL] [Abstract][Full Text] [Related]
12. Safety and immunogenicity of the novel tuberculosis vaccine ID93 + GLA-SE in BCG-vaccinated healthy adults in South Africa: a randomised, double-blind, placebo-controlled phase 1 trial.
Penn-Nicholson A; Tameris M; Smit E; Day TA; Musvosvi M; Jayashankar L; Vergara J; Mabwe S; Bilek N; Geldenhuys H; Luabeya AK; Ellis R; Ginsberg AM; Hanekom WA; Reed SG; Coler RN; Scriba TJ; Hatherill M;
Lancet Respir Med; 2018 Apr; 6(4):287-298. PubMed ID: 29595510
[TBL] [Abstract][Full Text] [Related]
13. Two novel HLA-DQ2.5-restricted gluten T cell epitopes in the DQ2.5-glia-γ4 epitope family.
Qiao SW; Sollid LM
Immunogenetics; 2019 Nov; 71(10):665-667. PubMed ID: 31673720
[TBL] [Abstract][Full Text] [Related]
14. Safety, pharmacokinetics, and antiviral effects of ABI-H0731, a hepatitis B virus core inhibitor: a randomised, placebo-controlled phase 1 trial.
Yuen MF; Agarwal K; Gane EJ; Schwabe C; Ahn SH; Kim DJ; Lim YS; Cheng W; Sievert W; Visvanathan K; Ruby E; Liaw S; Yan R; Huang Q; Colonno R; Lopatin U
Lancet Gastroenterol Hepatol; 2020 Feb; 5(2):152-166. PubMed ID: 31711752
[TBL] [Abstract][Full Text] [Related]
15. Assessing possible celiac disease by an HLA-DQ2-gliadin Tetramer Test.
Brottveit M; Ráki M; Bergseng E; Fallang LE; Simonsen B; Løvik A; Larsen S; Løberg EM; Jahnsen FL; Sollid LM; Lundin KE
Am J Gastroenterol; 2011 Jul; 106(7):1318-24. PubMed ID: 21364548
[TBL] [Abstract][Full Text] [Related]
16. Design of azidoproline containing gluten peptides to suppress CD4+ T-cell responses associated with celiac disease.
Kapoerchan VV; Wiesner M; Overhand M; van der Marel GA; Koning F; Overkleeft HS
Bioorg Med Chem; 2008 Feb; 16(4):2053-62. PubMed ID: 18037302
[TBL] [Abstract][Full Text] [Related]
17. Gliadin Nanoparticles Induce Immune Tolerance to Gliadin in Mouse Models of Celiac Disease.
Freitag TL; Podojil JR; Pearson RM; Fokta FJ; Sahl C; Messing M; Andersson LC; Leskinen K; Saavalainen P; Hoover LI; Huang K; Phippard D; Maleki S; King NJC; Shea LD; Miller SD; Meri SK; Getts DR
Gastroenterology; 2020 May; 158(6):1667-1681.e12. PubMed ID: 32032584
[TBL] [Abstract][Full Text] [Related]
18. Different binding motifs of the celiac disease-associated HLA molecules DQ2.5, DQ2.2, and DQ7.5 revealed by relative quantitative proteomics of endogenous peptide repertoires.
Bergseng E; Dørum S; Arntzen MØ; Nielsen M; Nygård S; Buus S; de Souza GA; Sollid LM
Immunogenetics; 2015 Feb; 67(2):73-84. PubMed ID: 25502872
[TBL] [Abstract][Full Text] [Related]
19. Safety, pharmacokinetics, and immunogenicity of a co-formulated cocktail of three human monoclonal antibodies targeting Ebola virus glycoprotein in healthy adults: a randomised, first-in-human phase 1 study.
Sivapalasingam S; Kamal M; Slim R; Hosain R; Shao W; Stoltz R; Yen J; Pologe LG; Cao Y; Partridge M; Sumner G; Lipsich L
Lancet Infect Dis; 2018 Aug; 18(8):884-893. PubMed ID: 29929783
[TBL] [Abstract][Full Text] [Related]
20. HLA-DQ2.5 genes associated with celiac disease risk are preferentially expressed with respect to non-predisposing HLA genes: Implication for anti-gluten T cell response.
Pisapia L; Camarca A; Picascia S; Bassi V; Barba P; Del Pozzo G; Gianfrani C
J Autoimmun; 2016 Jun; 70():63-72. PubMed ID: 27083396
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
